Cellebrite reports that public perceptions that its products were being used in ways incompatible with human rights, “could adversely affect our reputation, revenue and results of operations.”

Cellebrite’s plan to go public poses a test for the SEC, stock exchanges, and investors as to whether they can deliver the sustainable financial system that responsible investors demand.

This open letter presents an opportunity to set a positive precedent for transparency and accountability for human rights violations and risks of publicly‐traded companies (especially in the technology sector), currently being addressed by the U.S. Senate.

Contact Hinako Sugiyama for more information. 

Please join the collaboration to see more details on how you can get involved.